PEMAZYRE (Pemigatinib)

General Description

Pemazyre (pemigatinib) is an oral targeted therapy used to treat adults with specific types of cholangiocarcinoma (bile duct cancer) that have a fibroblast growth factor receptor 2 (FGFR2) gene fusion or rearrangement, and whose cancer has progressed after at least one prior treatment.

Getting Pemazyre (pemigatinib) in India

Pemazyre is approved in the U.S., Europe, and other countries, but it is not yet commercially available in India. However, eligible patients in India may access this important therapy through the Named Patient Program (NPP).

MitoGENE helps patients obtain Pemazyre legally and safely, in collaboration with their treating doctor. We assist with documentation, import coordination, and delivery—ensuring full compliance with Indian regulatory guidelines.

If you or a loved one needs Pemazyre, MitoGENE is here to guide you through every step of the process.

Disease Indications:Cholangiocarcinoma (bile duct cancer)

Manufacturer:Incyte Corporation

Usage:Oral

Medicine Approved by:

• U.S. Food and Drug Administration (FDA)
• European Medicines Agency (EMA)
• Health Canada
• Therapeutic Goods Administration (TGA), Australia

Available Dosage Form & Package:

• 4.5 mg, 9 mg, 13.5 mg tablets – Packaged in 14- or 28-day supplies

Shipping:

Room Temperature Shipping. Pemazyre is shipped under controlled room temperature conditions (15°C to 25°C) using standard logistics procedures.